Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,078 | 4 | 94.3% |
| Education | $124.97 | 2 | 5.7% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,078 | 4 | $0 (2020) |
| Lilly USA, LLC | $113.05 | 1 | $0 (2017) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $1,406 | 1 | Novartis Pharmaceuticals Corporation ($1,406) |
| 2018 | $672.36 | 3 | Novartis Pharmaceuticals Corporation ($672.36) |
| 2017 | $113.05 | 1 | Lilly USA, LLC ($113.05) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 11/19/2020 | Novartis Pharmaceuticals Corporation | — | — | In-kind items and services | $1,406.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 06/20/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | NIR178X (Drug) | — | In-kind items and services | $143.25 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT | ||||||
| 06/03/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | NIR178X (Drug) | — | In-kind items and services | $394.29 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT | ||||||
| 02/13/2018 | Novartis Pharmaceuticals Corporation | NIR178X (Drug) | — | In-kind items and services | $134.82 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT | ||||||
| 03/01/2017 | Lilly USA, LLC | CYRAMZA (Drug) | Education | In-kind items and services | $113.05 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,406 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $537.54 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $134.82 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 282 | 528 | $135,750 | $62,488 |
| 2022 | 3 | 326 | 543 | $124,776 | $60,259 |
| 2021 | 4 | 321 | 610 | $116,804 | $60,317 |
| 2020 | 4 | 342 | 569 | $119,693 | $50,650 |
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 139 | 376 | $90,101 | $43,043 | 47.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 113 | 113 | $38,734 | $16,455 | 42.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 30 | 39 | $6,915 | $2,990 | 43.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 139 | 304 | $69,071 | $35,304 | 51.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 97 | 97 | $31,772 | $14,286 | 45.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 90 | 142 | $23,933 | $10,669 | 44.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 109 | 216 | $46,620 | $25,428 | 54.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 107 | 271 | $41,913 | $21,567 | 51.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 71 | 71 | $23,075 | $10,521 | 45.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 34 | 52 | $5,196 | $2,800 | 53.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 136 | 291 | $62,565 | $26,533 | 42.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 97 | 97 | $31,525 | $13,245 | 42.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 85 | 143 | $21,879 | $9,258 | 42.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 24 | 38 | $3,724 | $1,615 | 43.4% |
About Tawee Tanvetyanon
Tawee Tanvetyanon is a Hematology & Oncology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750303905.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Tawee Tanvetyanon has received a total of $2,203 in payments from pharmaceutical and medical device companies, with $11.92 received in 2021. These payments were reported across 6 transactions from 3 companies. The most common payment nature is "" ($2,078).
As a Medicare-enrolled provider, Tanvetyanon has provided services to 1,271 Medicare beneficiaries, totaling 2,250 services with total Medicare billing of $233,713. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Tampa, FL
- Active Since 07/24/2006
- Last Updated 09/30/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1750303905
Products in Payments
- NIR178X (Drug) $672.36
- CYRAMZA (Drug) $113.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tampa
Damian Laber, Md, MD
Hematology & Oncology — Payments: $1.4M
Eduardo Sotomayor, Md, MD
Hematology & Oncology — Payments: $447,992
Ariel Grajales-Cruz
Hematology & Oncology — Payments: $424,303
Dr. Kendra Sweet, M.d, M.D
Hematology & Oncology — Payments: $215,309
Khaldoun Almhanna, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $173,538
Hayder Saeed, M.d, M.D
Hematology & Oncology — Payments: $140,365